Polyelectrolyte-Drug Complexes of Lambda Carrageenan and Basic Drugs: Relevance of Particle Size and Moisture Content on Compaction and Drug Release Behavior

被引:6
作者
Bonferoni, M. C. [1 ]
Sandri, G.
Rossi, S.
Ferrari, F.
Caramella, C.
Aguzzi, C. [2 ]
Viseras, C. [2 ]
机构
[1] Univ Pavia, Sch Pharm, Dept Pharmaceut Chem, I-27100 Pavia, Italy
[2] Univ Granada, Dept Pharm Pharmaceut Technol, E-18071 Granada, Spain
关键词
polyelectrolyte-drug complexes; lambda carrageenan; diltiazem; metoprolol; controlled release;
D O I
10.1080/03639040801974337
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interaction between polyelectrolytes (PE) and oppositely charged drugs (D) results in complexes (PE-D) that can be exploited in controlled release drug delivery systems. The aim of this work is to better understand the relevance of some preparative parameters such as moisture content and particle size on the performance of two PE-D complexes to be used in oral controlled release tablets. PE-D complexes containing diltiazem HCL (DTZ) or metoprolol tartrate (MTP) and lambda carrageenan were obtained at two particle size levels (<45 mu m and 75-105 mu m), maintained at different values of relative humidity (RH) (11, 52, 75, and 93%), and compressed. The tablets were characterized for porosity, hardness, moisture content, and contact angle. Drug release profiles were fitted to the Weibull equation, and a factorial design was used to understand the relevance of particle size and RH% on release rate as a function of medium pH. The results indicated that the hydrophobic character of the complex between PE and D depended on the drug and in the present case was more pronounced for DTZ than for MTP. This in turn affected the possible release mechanism and therefore the importance of particle size and RH%.
引用
收藏
页码:1188 / 1195
页数:8
相关论文
共 18 条
[1]  
Aguzzi C, 2002, AAPS PHARMSCITECH, V3, pE27
[2]  
BETTINI R, 2003, AAPS ANN M SALT LAK
[3]  
BOLTON S, 1997, DRUGS PHARM SCI PHAR
[4]   On the employment of λ carrageenan in a matrix system.: III.: Optimization of a λ carrageenan-HPMC hydrophilic matrix [J].
Bonferoni, MC ;
Rossi, S ;
Ferrari, F ;
Bertoni, M ;
Bolhuis, GK ;
Caramella, C .
JOURNAL OF CONTROLLED RELEASE, 1998, 51 (2-3) :231-239
[5]   Characterization of a diltiazem-lambda carrageenan complex [J].
Bonferoni, MC ;
Rossi, S ;
Ferrari, F ;
Bettinetti, GP ;
Caramella, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 200 (02) :207-216
[6]   Development of oral controlled-release tablet formulations based on diltiazem-carrageenan complex [J].
Bonferoni, MC ;
Rossi, S ;
Ferrari, F ;
Caramella, C .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2004, 9 (02) :155-162
[7]   EQUILIBRIUM MOISTURE-CONTENT OF PHARMACEUTICAL EXCIPIENTS [J].
CALLAHAN, JC ;
CLEARY, GW ;
ELEFANT, M ;
KAPLAN, G ;
KENSLER, T ;
NASH, RA .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1982, 8 (03) :355-369
[8]   PHYSICAL CHARACTERIZATION OF CARTEOLOL - EUDRAGIT(R) L-BINDING INTERACTION [J].
HOLGADO, MA ;
FERNANDEZAREVALO, M ;
ALVAREZFUENTES, J ;
CARABALLO, I ;
LLERA, JM ;
RABASCO, AM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 114 (01) :13-21
[9]   Swellable drug-polyelectrolyte matrices (SDPM) - Characterization and delivery properties [J].
Jimenez-Kairuz, AF ;
Llabot, JM ;
Allemandi, DA ;
Manzo, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 288 (01) :87-99
[10]   Drug release from drug-polyanion complex tablets: poly(acrylamido-2-methyl-1-propanesulfonate sodium -co- methyl methacrylate) [J].
Konar, N ;
Kim, CJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 57 (02) :141-150